SMS Mobile Technology for Vaccine Coverage and Acceptance
NCT01663636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321
Last updated 2018-12-31
Summary
To pilot test a mobile phone SMS (Short Message Service) system that will provide periodical messaging texts to mothers or custodians of infants who come for their first dose vaccines within the first 3 months of life to improve timely immunization coverage, vaccine acceptance and ensure vaccine safety monitoring. The intervention will include a "cloud-based" information system alimented by mobile phone data entry at the health post nurse level, that links child vaccination status and is able to remind parents and nurses of the need for next vaccination appointment and provide a system for reporting of adverse events following immunization in the immediate post-vaccination period.
Conditions
- Adherence to Vaccination Schedules
Interventions
- BEHAVIORAL
-
SMS message reminding mothers to come for their scheduled vaccines
Reminder
Sponsors & Collaborators
-
University of Colorado, Denver
lead OTHER
Principal Investigators
-
Edwin J Asturias, MD · University of Colorado School of Medicine
-
Ingrid L Contreras-Roldan, MD · University del Valle, Guatemala
Eligibility
- Min Age
- 1 Month
- Max Age
- 12 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2014-06-30
- Completion
- 2015-06-30
Countries
- Guatemala
Study Locations
More Related Trials
-
10+10+30 Infant Vaccines Communication Via Radio in Ethiopia
NCT04913714 ·Status: COMPLETED ·Phase: NA
-
Making Decisions About the Measles-Mumps-Rubella Vaccine
NCT01369394 ·Status: COMPLETED ·Phase: NA
-
Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18
NCT06347627 ·Status: COMPLETED ·Phase: NA
-
Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico
NCT00436358 ·Status: COMPLETED
-
Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination
NCT03209713 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
NCT01428908 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine
NCT02153866 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
NCT01411241 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
NCT06621654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Child Vaccination Scheduling in China
NCT07141875 ·Status: NOT_YET_RECRUITING
-
Khushi Baby (KB): Novel Mobile Health Solution for Vaccination Record Keeping in India
NCT02518178 ·Status: UNKNOWN ·Phase: NA
-
Testing The Effectiveness Of Two Interventions To Reduce Vaccine Hesitancy Among Adolescents
NCT06155877 ·Status: COMPLETED ·Phase: NA
-
Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB
NCT00359983 ·Status: COMPLETED ·Phase: PHASE3
-
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
NCT00614614 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
NCT02692859 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)
NCT05916326 ·Status: COMPLETED ·Phase: PHASE3
-
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
NCT00718666 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old
NCT02806531 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
NCT00345683 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants
NCT05189548 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
NCT01226953 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers
NCT00135564 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
NCT01732198 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children
NCT01125527 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
NCT00345579 ·Status: COMPLETED ·Phase: PHASE3